Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 14.
Oncotarget’s Volume 12, Issue #14
New Publications
Cover (Research Paper): Esomeprazole enhances the effect of ionizing radiation to improve tumor control
Origin: Texas, United States
Institutions: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, Texas Children’s Hospital
Quote: “Here, we evaluated the radiosensitizing effect of the FDA-approved drug esomeprazole in normal and radioresistant human head and neck squamous cell carcinoma (HNSCC) cells in vitro, and in a mouse model of HNSCC.”
Research Paper: Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer
Origin: Maryland, North Carolina, United States; Belém, São Paulo, Brazil
Institutions: Johns Hopkins University, Federal University of Pará, University of North Carolina Hospitals, Universidade Federal de São Paulo
Quote: “The five-year survival rate for metastatic pancreatic cancer is currently only 3%, which increases to 13% with local invasion only and to 39% with localized disease at diagnosis. Here we evaluated repurposed mebendazole, an approved anthelminthic drug, to determine how mebendazole might work at the different stages of pancreatic cancer formation and progression.”
Research Paper: MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
Origin: Toronto, North York, Canada
Institutions: Sunnybrook Health Sciences Centre, University of Toronto, York University, Ryerson University
Quote: “Radiomics involving quantitative analysis of imaging has shown promises in oncology to serve as non-invasive biomarkers. We investigated whether pre-treatment T2-weighted magnetic resonance imaging (MRI) can be used to predict response to neoadjuvant chemotherapy (NAC) in breast cancer.”
Research Paper: The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma
Origin: Copenhagen, Denmark
Institution: Rigshospitalet and University of Copenhagen
Quote: “The development of tumor-targeted probes that can efficiently reach cancerous tissue is an important focus of preclinical research. […] In this study, ICG-Glu-Glu-AE105 was evaluated as photothermal agent in a subcutaneous mouse model of human glioblastoma.”
Research Paper: Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia
Origin: Naples, Italy
Institution: University of Campania Luigi Vanvitelli
Quote: “In this study we tested cytarabine, the most commonly used anticancer drug in AML, with both DFX, one of the most diffused iron chelators in leukemia, and ELT, an emerging iron chelating agent, in THP-1 cell line. The purpose of our study was to investigate the possibility to combine iron chelation with standard anti-leukemic treatments, to ameliorate the therapeutic outcome for leukemic pediatric patients, contributing to improve therapy response and consequent life quality.”
Research Paper: Prokineticin-1 induces normal lymphangiogenic activity and is involved in lymphangiogenesis and lymph node metastasis in colorectal cancer
Origin: Fukui, Japan
Institutions: University of Fukui, Fukui Health Science University
Quote: “Prokineticin family correlates with important roles in several biological processes, including homeostasis. We discovered novel functions of prokineticin1 (PROK1) in lymphangiogenesis and lymphnode metastasis in colorectal cancer.”
Research Paper: Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase
Origin: Xi’an, Shanghai, Karamay, Kunshan, China
Institutions: The Second Affiliated Hospital of Xi’an Jiaotong University, Shanghai Pudong Hospital of Fudan University, Karamay Central Hospital of Xinjiang, Community Health Service Center of Jinxi Town
Quote: “Recent study suggested that type 2 diabetes (T2DM) attributed to body mass index (BMI) could be influenced by liver aminotransferase. We aim to ascertain the cut-off point of BMI associated with T2DM and the influence of both elevated aminotransferase (AST) and alanine aminotransferase (ALT).”
Review: Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment
Origin: Washington, D.C., United States
Institution: Georgetown University Medical Center
Quote: “Here we review studies on molecular mechanisms of CPZ’s [chlorpromazine] action on key proteins involved in cancer, including p53, YAP, Ras protein, ion channels, and MAPKs. We discuss common and overlapping signaling pathways of CPZ’s action, its cancer-type specificity, antitumorigenic effects of CPZ reported in animal models and population studies on the rate of cancer in psychiatric patients. We also discuss the potential benefits and limitations of repurposing CPZ for cancer treatment.”
Research Perspective: Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives
Origin: Southampton, United Kingdom
Institutions: University of Southampton, Cancer Research UK and NIHR Southampton Experimental Cancer Medicine Centre
Quote: “In this editorial, we highlight current limitations in our understanding of CAF [Cancer associated fibroblasts] heterogeneity, and discuss the potential and possible approaches for CAF-directed therapy.”
Research Perspective: A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies
Origin: Pavia, Italy
Institution: University of Pavia
Quote: “This editorial aims to summarize the research that in the last 7–8 years has led to the development of a new DEB-based [Dynamic Energy Budget] framework modeling the tumor-in-host growth dynamics and the cachexia onset in preclinical animal models during anticancer treatments [14–16].”
Click here to read Oncotarget’s Volume 12, Issue #14.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
—
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact media@impactjournals.com.
